52 results about "Oral tablets" patented technology

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

The invention relates to the field of biological medicine, in particular to application of quercetagetin in preparation of medicine for preventing hyperuricemia and / or hyperuricemia related diseases. The invention discovers that quercetagetin has a prevention or improvement effect on hyperuricemia and related diseases for the first time. The result of the specific embodiment of the invention shows that the quercetagetin has a good uric acid reducing effect, obviously reduces the activity of uric acid generation participating enzyme, regulates the expression of uric acid transporter mRNA, improves liver injury and kidney injury caused by hyperuricemia, can prevent or relieve hyperuricemia or hyperuricemia-related diseases, and has a good application prospect. The composition can be used for preparing oral tablets and effervescent tablets.

This utility model discloses a raw material preparation device for oral tablet processing, relating to the field of tablet processing technology. It includes: a device support frame for mounting and fixing a lifting sleeve mechanism, a flow guiding and output mechanism, and a pushing and stirring mechanism; and a lifting sleeve mechanism comprising an outer sleeve slidably disposed vertically inside an upper flow guide hopper and slidably sleeved on the outside of a rotating disk and a sieve plate. Two sets of synchronously moving lifting components are arranged on both sides of the outer sleeve. Each set of lifting components includes an L-shaped side plate fixedly disposed on the side of the worktable, and an electric push rod is fixedly disposed at the bottom of the L-shaped side plate. This utility model can conveniently output large-particle raw materials and prepared raw materials after screening and preparation, saving manpower while effectively improving preparation efficiency. It also provides a more thorough discharge with less residue.

This disclosure provides crystalline forms of a compound of Formula (A), and pharmaceutical compositions thereof. This disclosure further provides methods for their preparation and use in methods of treatment, prophylaxis, or delay in onset or progression of HIV infection or AIDS in a subject. This disclosure further provides dosage forms, such as oral tablets, of a compound of Formula (A) and its crystalline forms.

A nano abiraterone acetate composition, a preparation method therefor, and an oral tablet thereof. The composition comprises abiraterone acetate, a suspending aid, a surfactant, and a stabilizer in percentage by weight of 1:(0.1-4):(6-20):(0.01-0.1), and is prepared by wet grinding, drying, and dewatering. The oral bioavailability of the product is improved by adding a cholate absorption-promoting agent, such that the influence of food on drug absorption is reduced.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are methods for making the tablets comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers, e.g., comprising slugged tablets, wherein the slugged tablets have greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, or 100% of the slugged tablets meet specifications; target width of 10 to 12 mm, or 11 mm; target weight of approximately 475 to 525 mg; and thickness range of approximately 4 to 6 mm, 4.5 to 5.5 mm or 5 mm. Pharmaceutical composition(s) in the form an oral tablet or capsule comprising N-acetylcysteine amide (NACA) for administration of the pharmaceutical composition to a human.

The invention belongs to the field of medicines, and particularly discloses application of ImP (Imidazole Propionic Acid) in preparation of medicines for preventing or treating metabolic syndrome related diseases, aiming at the problems that the existing anti-obesity medicines are large in side effect, limited in curative effect and the like, and metabonomics research finds that the peripheral blood ImP level in a high-fat diet induced obesity model is remarkably reduced. A zebra fish model (250 [mu] M) and a human fat cell experiment (10-1000 [mu] M) prove that ImP significantly reduces the lipid accumulation rate by more than 40% (Plt; 0.01) of the substrate. The pharmaceutical composition can be prepared into dosage forms such as oral tablets (for example, each tablet containing 50 mg of ImP), sustained-release injections and the like, and can be theoretically combined with orlistat and other medicines for use. Compared with the traditional therapy, the invention reveals the lipid metabolism regulation function of ImP for the first time, and the ImP has the advantages of strong targeting property (IC50 = 120 mu M), high safety (LD50gt; 2000mg / kg) and the like, and a brand new microbial metabolite intervention strategy is provided for obesity and related metabolic diseases.

The invention relates to amitriptyline gel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides amitriptyline gel. The amitriptyline gel is prepared from the following components in parts by mass: 2 to 8 parts of amitriptyline hydrochloride, 16 to 24 parts of glycerol, 2 to 8 parts of hydroxypropyl methylcellulose, 16 to 24 parts of 70 to 80 percent ethanol solution, 0.05 to 0.15 part of ethylparaben, 0.2 to 0.8 part of laurocapram and 36 to 64 parts of water. The amitriptyline gel plaster prepared from the amitriptyline gel can effectively relieve postherpetic neuralgia, and compared with traditional oral tablets, the amitriptyline gel plaster can effectively reduce side effects.

The present invention relates to a pharmaceutical composition comprising ramelteon and a nasal administration formulation. The pharmaceutical composition comprises ramelteon and polyethylene glycol. The pharmaceutical composition of the present invention has high stability and can be used to prepare a pharmaceutical formulation that meets the specifications for nasal administration formulations. Compared with oral tablets, the pharmaceutical composition of the present invention features improved bioavailability of ramelteon and a targeted concentration in brain tissue.

An oral dosage tablet for delivery of hydrophobic active ingredients to a patient and method of forming the same are described. The oral dosage tablet includes one or more layers of an active ingredie

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fdlers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / mL after administration of the pharmaceutical composition to a human.

The present application discloses a composition, oral tablets and their preparation method and application, and belongs to the field of food and drug technology. The composition includes sodium sulfate, magnesium sulfate and potassium chloride, and the weight ratio of the sodium sulfate, magnesium sulfate and potassium chloride is (5-10): (1-2): (0.5-1.5); the particle size of the sodium sulfate is less than 700 μm, the purity is not less than 98%, and the moisture content is less than 0.5%; the particle size of the magnesium sulfate is less than 700 μm, the purity is not less than 98.5%, and the moisture content is less than 5.0%; the particle size of the potassium chloride is less than 700 μm, the purity is not less than 98.5%, and the moisture content is less than 1.0%. Each component function is fully exerted, improves the intestinal environment, restores intestinal health, and alleviates functional constipation.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / ml after administration of the pharmaceutical composition to a human.

Disclosed are formulations in the form of mucoadhesive tablets useful for treating symptoms caused by xerostomia (dry mouth). The tablets according to the invention comprise hyaluronic acid, choline alfoscerate and ascorbyl palmitate, and are characterised by two concave surfaces that adapt to the oral and gingival mucosa so as to adhere to the oral vestibules or the palate.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are methods for making the tablets comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers, e.g., comprising slugged tablets, wherein the slugged tablets have greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, or 100% of the slugged tablets meet specifications; target width of 10 to 12 mm, or 11 mm; target weight of approximately 475 to 525 mg; and thickness range of approximately 4 to 6 mm, 4.5 to 5.5 mm or 5 mm. Pharmaceutical composition(s) in the form an oral tablet or capsule comprising N-acetylcysteine amide (NACA) for administration of the pharmaceutical composition to a human.

The present disclosure relates to oral naproxen sodium tablets containing roller compacted particles, methods of making the same, and methods of using the same. Naproxen sodium tablets are formulated and prepared by dry granulation, in particular roller compaction. The naproxen sodium tablet is produced by combining a dry granulation compatible excipient with a roller compaction method, and compared with commercially available oral naproxen sodium tablets prepared by a standard wet granulation method, the naproxen sodium tablet has the advantages that the dissolution rate general situation is enhanced, and the disintegration time is shortened.

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

The invention related to an oral colon targeted tablet comprising a tablet core coated with a film-coating composition, said tablet core comprising a powder of a therapeutic protein co-dried with a substituted cyclodextrin, and said film-coating coating composition comprising a water-insoluble polymer and a soluble fiber. It also related to a process for making such tablets, and to the use thereof as a medicament.

Provided are oral tablets comprising naproxen sodium, mannitol, a superdisintegrant, and a lubricant. The oral tablets described herein to not comprise a glidant (e.g. colloidal silicon dioxide). These oral tablets may be manufactured using the process of mixing naproxen sodium, mannitol, a superdisintegrant, and magnesium stearate in a continuous in-line mixer to form a tableting mixture; transferring the tableting mixture to a tablet press including three or more compression rollers; and pressing the tableting mixture into naproxen sodium tablets.

The present invention provides a drug for treating non-small cell lung cancer, belonging to the field of medicine. The drug's raw materials include gefitinib and andrographolide, wherein the concentration of gefitinib is 12-20 μM and the concentration of andrographolide is 200-250 μM. The drug is in the form of an oral liquid preparation or an oral tablet. Experimental results show that the drug provided by the present invention has a significant inhibitory effect on the expression of apoptosis-related proteins and genes in PC9 / G cells, with a greater inhibitory effect than gefitinib or andrographolide alone, indicating a certain synergistic relationship between the two.

The invention relates to an orally administered tablet suitable for active pharmaceutical ingredients comprising a particle population, the particle population comprising a) directly compressible sugar alcohol particles (DC), b) not directly compressible sugar alcohol particles (non-DC) and c) particles comprising a gum base, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in saliva-induced generation upon chewing the tablet, wherein the tablet is designed to be chewed into a coherent residue containing water-insoluble components.

The present disclosure provides a method of making an oral tablet comprising mixing a macromolecule with sodium caprate to form a mixture, and compressing the mixture into a tablet, wherein the sodium caprate is Form A. The present disclosure also provides a tablet made by the process provided herein. Also provided is a composition comprising sodium caprate and a macromolecule.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the prevention of a human immunodeficiency virus (HIV) infection in a patient.

The invention provides a tadalafil and fasudil pharmaceutical composition as well as a preparation method and application thereof, and belongs to the technical field of preparation of pharmaceutical preparations. Through research, the applicant finds that when the tadalafil and the fasudil are combined for treating the pulmonary arterial hypertension, a synergistic effect can be generated, and the improvement effect is superior to that of single use of one of the medicines. Moreover, the invention provides a preparation process of a tablet of the pharmaceutical composition, and the tablet comprises the following components: 1-5% of tadalafil, 10-25% of fasudil, 60-75% of a filler, 1-4% of an adhesive, 5-8% of a disintegrating agent, 0.5-2.0% of a lubricant and 0.1-0.5% of a solubilizer. According to the preparation process, auxiliary materials are cheap and easy to obtain, the process is simple, large-scale production is easy, the prepared pharmaceutical composition is an oral tablet, and the problems that the fasudil injection is inconvenient to take and the solution is easy to degrade under illumination are solved.

The invention provides an OAB-14 composition which comprises OAB-14, the particle size d (0.5) of the OAB-14 is 1-2998 nm, and the particle size d (0.9) of the OAB-14 is 2-5532 nm. The OAB-14 is further prepared into various dosage forms such as oral tablets, capsules, pellets, granules, dry suspensions, suspensions and the like. The particle size d (0.5) of the OAB-14 raw material is reduced to be 1-2998 nm, the particle size d (0.9) of the OAB-14 raw material is reduced to be 2-5532 nm, the surfactant is added, the dissolution rate of the raw material is increased, the adhesion of the raw material on the gastrointestinal wall is improved, the bioavailability is increased by 217.91%, the same medicine effect is achieved, and the dosage of the suspension is 40% of that of the raw material medicine.

Pharmaceutical compositions of semaglutide or a salt thereof for intranasal administration for the treatment of diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), or neurodegenerative diseases. The method of delivering semaglutide by the intranasal route avoids repeated injections and improves systemic absorption of semaglutide compared to oral tablets.